表紙:PEG化タンパク質の世界市場(2022年~2029年)
市場調査レポート
商品コード
1065223

PEG化タンパク質の世界市場(2022年~2029年)

Global PEGylated Proteins Market - 2022-2029

出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.51円
PEG化タンパク質の世界市場(2022年~2029年)
出版日: 2022年05月07日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のPEG化タンパク質市場について調査分析し、市場力学、業界分析、市場分析、競合情勢など、体系的な情報を提供しています。

目次

第1章 世界のPEG化タンパク質の調査手法と範囲

  • 調査手法
  • 調査の目的と調査範囲

第2章 世界のPEG化タンパク質市場-市場の定義と概要

第3章 世界のPEG化タンパク質市場-エグゼクティブサマリー

  • 市場の内訳:製品タイプ別
  • 市場の内訳:アプリケーション別
  • 市場の内訳:エンドユーザー別
  • 市場の内訳:地域別

第4章 世界のPEG化タンパク質市場-市場力学

  • 市場に影響を与える要因
    • 促進要因
    • 抑制要因
    • 市場機会
    • 影響分析

第5章 世界のPEG化タンパク質市場-業界分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • PEST分析

第6章 世界のPEG化タンパク質市場-COVID-19分析

  • 市場のCOVID-19分析
    • COVID-19以前の市場シナリオ
    • 現在のCOVID-19の市場シナリオ
    • COVID-19以後の市場シナリオ/将来の市場シナリオ
  • COVID-19における価格の力学
  • 需要と供給のスペクトル
  • パンデミック時の市場に関連する政府のイニシアチブ
  • メーカーの戦略的イニシアチブ
  • 結論

第7章 世界のPEG化タンパク質市場:製品タイプ別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%):製品タイプ別
    • 市場魅力指数:製品タイプ別
  • 消耗品*
    • イントロダクション
    • 市場規模分析、100万米ドル(2020年~2029年)、および前年比成長分析(%)(2020年~2028年)
  • PEG化試薬
    • 単機能直鎖型PEG
    • 二官能性PEG
    • マルチアーム型PEG
    • 分岐型PEG
    • その他のPEG化試薬
  • PEG化キット
  • サービス

第8章 世界のPEG化タンパク質市場:タンパク質タイプ別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%):タンパク質タイプ別
    • 市場魅力指数:タンパク質タイプ別
  • コロニー刺激因子*
    • イントロダクション
    • 市場規模分析、100万米ドル(2020年~2029年)、および前年比成長分析(%)(2020年~2028年)
  • インターフェロン
  • エリスロポエチン
  • mAbs
  • 組換え型第VIII因子
  • その他

第9章 世界のPEG化タンパク質市場:エンドユーザー別

  • イントロダクション
    • 市場規模分析、および前年比成長分析(%):エンドユーザー別
    • 市場魅力指数:エンドユーザー別
  • 製薬企業およびバイオテクノロジー企業*
    • イントロダクション
    • 市場規模分析、100万米ドル(2020年~2029年)、および前年比成長分析(%)(2020年~2028年)
  • CRO
  • 学術研究施設

第10章 世界のPEG化タンパク質市場:地域別

  • イントロダクション
    • 市場規模分析、100万米ドル(2020年~2029年)、および前年比成長分析(%)(2020年~2028年):地域別
    • 市場魅力指数:地域別
  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東とアフリカ

第11章 世界のPEG化タンパク質市場-競合情勢

  • 競合シナリオ
  • 主な開発と戦略
  • 企業シェア分析
  • 製品のベンチマーク
  • 注目すべき主要企業
  • 破壊的技術を持つ企業

第12章 世界のPEG化タンパク質市場-企業プロファイル概要

  • Thermo Fisher Scientific Inc*
    • 企業概要
    • 製品ポートフォリオおよび説明
    • 主要ハイライト
    • 財務概要
  • Merck KGaA
  • NOF America Corporation
  • JenKem Technology USA Inc
  • Creative PEGworks
  • Celares GmbH
  • Quanta BioDesign, Ltd

第13章 世界のPEG化タンパク質市場-DataM

  • 付録
  • 当社・サービスについて
  • お問い合わせ
目次
Product Code: DMPH4857

Market Overview

The global PEGylated proteins market size was worth US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

PEGylation is the process of binding or alteration of biological molecules by conjugation with polyethylene glycol is known as PEGylation. PEGylation enhances the stability and solubility of the drug and declines immunogenicity by changing the molecule's electrostatic binding, confirmation, and hydrophobicity.

Market Dynamics

The global PEGylated proteins market growth is driven by the increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing in adoption of protein-based drugs over non-protein-based drugs and increase of protein stability and circulating half-life with the help of PEGylation are the major drivers of market.

Increasing adoption of PEGylated protein-based drugs is expected to hold the largest share in this market segment

Increasing adoption of PEGylated protein-based drugs due to increased stability and circulating half-life, and awareness on strategies to improve protein stability and circulating half-life, are expected to boost the market growth during the forecast period. For instance, Mabwell Bioscience Co., Ltd., in September 2020, began the phase III clinical study to investigate the immunogenicity, safety, and hemostatic efficacy of PEGylated recombinant FVIII (BAX 855) in the patients who were previously left untreated and meet the requirements of being less than 6 years old and have severe hemophilia A. In addition, the increasing adoption of PEGylated protein to treat various chronic diseases will further fuel the market, as the number of people infected with chronic disease is on a rise. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020.

Failures in drug development is likely to hinder the market growth

The development of drugs is a complex and challenging process. The chances of a drug being developed during the first trial are rare as failures in drug development are very prevalent. The overall failure rate in drug development is around 96%, including a 90% failure rate during clinical development. The consequence of an expensive drug failure for pharmaceutical companies ranges from site closures, loss of jobs, and exhausting research and development budgets. Thus, failures in drug development and rising recalls of the therapeutic drugs might hamper the growth of the PEGylated proteins market during the forecast period.

COVID-19 Impact Analysis

The outbreak of coronavirus did not adversely affect the PEGylated Proteins Market. The demand for PEGylated proteins remained unaffected as they fall under necessities. Several research institutes conducted extensive research based on PEGylation technology in 2020. For instance, in a research study published in the Journal of General Virology, 2020, SARS-CoV-2 replication could be inhibited by low concentrations of PEG-IFN-alpha-2a that inhibit MERS-CoV replication in cell culture. The impact of COVID-19 on the PEGylated proteins market was minimal.

Segment Analysis

The colony-stimulating factors segment is expected to hold the largest share in this market segment

Colony-stimulating factors are substances that accelerate the production of blood cells and elevate their ability to function. They do not directly influence tumors but have a role in stimulating blood cells, and hence, these factors can be beneficial in supporting a person's immune system during cancer treatment. The increasing incidence of cancer across the globe has increased the demand for this segment, which will fuel the market growth for PEGylated proteins globally. According to Global cancer statistics, 2020, the number of cancer cases globally was estimated to be 19, 292,789, with nearly 9,958,133 deaths due to cancer. Thus, the need for colony-stimulating factors to effectively treat cancer will drive market growth.

Geographical Analysis

North America region holds the largest market share of global PEGylated proteins market

The North American region is expected to dominate the overall PEGylated protein market throughout the forecast period. The presence of key players, the high prevalence of chronic diseases in the region, established healthcare infrastructure, and growing awareness of advanced treatment options among the American population are key factors for its large share in the market. In this region, the United States holds the largest market share, and the large patient pool in the country is anticipated to stimulate the demand in this region. According to Globocan 2020, nearly 2,281,658 cancer cases were diagnosed in 2020, and cancer led to 612,390 deaths in the United States during the year. Breast cancer accounted for 253,465 new cases in 2020, followed by lung (227,875), prostate (209,512), and colon (101,809) cancers in the United States.

Moreover, the increasing geriatric population and the high incidence of chronic diseases are also expected to play a vital role in the growth of the studied market. According to the Population Reference Bureau's Population Bulletin: Aging in the United States, the total number of Americans aged 65 and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. Thus, the elderly population is more prone to chronic diseases, which surges the demand for advanced diagnostics and treatment planning.

Competitive Landscape

The global PEGylated proteins market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Merck KGaA, Thermo Fisher Scientific Inc., NOF America Corporation, JenKem Technology USA Inc., Creative PEGworks, and Celares GmbH, Quanta BioDesign, Ltd. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market. For instance, In August 2021, JenKem Technology provides large scale GMP manufacture of PEG derivatives for Lipid Nanoparticles (LNPs), and related PEG intermediates.

Global PEGylated Proteins Market - Key Companies to Watch

Thermo Fisher Scientific Inc

Overview: Thermo Fisher Scientific is global manufacturer and provider of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry. The company generated revenue of USD 32.3 billion in 2020, and invested USD 1.2 billion in R&D.

Product Portfolio: It offers thermo Scientific Pierce MS(PEG)n reagents are methyl-terminated, polyethylene glycol compounds (n equals 4 to 24 PEG units) activated as NHS esters for covalent pegylation of primary amines on proteins (e.g., lysines) or assay surfaces.

Why Purchase the Report?

Visualize the composition of the PEGylated proteins market segmentation by product type, protein type, end-user and region highlighting the key commercial assets and players.

Identify commercial opportunities in PEGylated proteins market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of PEGylated proteins market - level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players.

The global PEGylated proteins market report would provide an access to an approx. 46 market data table, 56 figures and 200 pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Market Segmentation

Global PEGylated Proteins Market - By Product Type

Consumables

PEGylation Reagents

Monofunctional Linear PEGs

Bifunctional PEGs

Multi-Arm PEGs

Branched PEGs

Other PEGylation Reagents

PEGylation Kits

Services

Global PEGylated Proteins Market - By Protein Type

Colony Stimulating Factors

Interferons

Erythropoietin

mAbs

Recombinant Factor VIII

Other Protein Type

Global PEGylated Proteins Market - By End-User

Pharmaceutical & Biotechnology Companies

CROs

Academic Research Institutes

Global PEGylated Proteins Market - By Region

North America

Europe

Asia-Pacific

Middle East & Africa

South America

Table of Contents

1. Global PEGylated Proteins Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global PEGylated Proteins Market - Market Definition and Overview

3. Global PEGylated Proteins Market - Executive Summary

  • 3.1. Market Snippet by Product Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Global PEGylated Proteins Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. Increasing adoption of PEGylated protein-based drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. Failures in drug development
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global PEGylated Proteins Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. PEST Analysis

6. Global PEGylated Proteins Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global PEGylated Proteins Market - By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Consumables*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. PEGylation Reagents
    • 7.3.1. Monofunctional Linear PEGs
    • 7.3.2. Bifunctional PEGs
    • 7.3.3. Multi-Arm PEGs
    • 7.3.4. Branched PEGs
    • 7.3.5. Other PEGylation Reagents
  • 7.4. PEGylation Kits
  • 7.5. Services

8. Global PEGylated Proteins Market - By Protein Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 8.1.2. Market Attractiveness Index, By Protein Type
  • 8.2. Colony Stimulating Factors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Interferons
  • 8.4. Erythropoietin
  • 8.5. mAbs
  • 8.6. Recombinant Factor VIII
  • 8.7. Other Protein Type

9. Global PEGylated Proteins Market - By End-user

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.1.2. Market Attractiveness Index, By End-user
  • 9.2. Pharmaceutical & Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. CROs
  • 9.4. Academic Research Institutes

10. Global PEGylated Proteins Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Protein Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

11. Global PEGylated Proteins Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Key Developments and Strategies
  • 11.3. Company Share Analysis
  • 11.4. Product Benchmarking
  • 11.5. Key Companies to Watch
  • 11.6. Company with disruptive technology

12. Global PEGylated Proteins Market- Company Profiles

  • 12.1. Thermo Fisher Scientific Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Merck KGaA
  • 12.3. NOF America Corporation
  • 12.4. JenKem Technology USA Inc
  • 12.5. Creative PEGworks
  • 12.6. Celares GmbH
  • 12.7. Quanta BioDesign, Ltd

LIST NOT EXHAUSTIVE

13. Global PEGylated Proteins Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us